Smokers clinical trials

Explore recruiting smokers clinical trials.

Recruiting smokers studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Smokers trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Czechia, Germany, Poland, Hungary, Spain, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)

Sweden, Romania, Spain, Italy, Germany, Poland +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)

Greece, Denmark, Netherlands, Poland, Belgium, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) (AERIFY-1)

Romania, Slovakia, Bulgaria, Italy, Czechia, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prospective, multicentre phase II study of de-escalation of primary chemoradiotherapy of squamous cell carcinoma of oropharynx (OPC) associated with human papilloma virus (HPV)

Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a, open-label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)

Belgium, Germany, Netherlands, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Smokers trials by city

Smokers in Toronto Smokers in Vancouver Smokers in Montreal Smokers in Calgary Smokers in Edmonton Smokers in Ottawa Smokers in Winnipeg Smokers in Quebec City Smokers in Hamilton Smokers in Kitchener Smokers in London Smokers in Halifax Smokers in New York Smokers in Los Angeles Smokers in Chicago Smokers in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease